The Long Run with Luke Timmerman

Ep192: Kate Haviland on Following the Science to Precision Immunology

Donnerstag, 8. Januar 2026 · 1 h 26

MP3

Shownotes

Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.

0:00 / 0:00